285 related articles for article (PubMed ID: 33109489)
1. Targeting the DNA Repair Enzyme Polymerase θ in Cancer Therapy.
Schrempf A; Slyskova J; Loizou JI
Trends Cancer; 2021 Feb; 7(2):98-111. PubMed ID: 33109489
[TBL] [Abstract][Full Text] [Related]
2. Polymerase θ Coordinates Multiple Intrinsic Enzymatic Activities during DNA Repair.
Zahn KE; Jensen RB
Genes (Basel); 2021 Aug; 12(9):. PubMed ID: 34573292
[TBL] [Abstract][Full Text] [Related]
3. Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance.
Zatreanu D; Robinson HMR; Alkhatib O; Boursier M; Finch H; Geo L; Grande D; Grinkevich V; Heald RA; Langdon S; Majithiya J; McWhirter C; Martin NMB; Moore S; Neves J; Rajendra E; Ranzani M; Schaedler T; Stockley M; Wiggins K; Brough R; Sridhar S; Gulati A; Shao N; Badder LM; Novo D; Knight EG; Marlow R; Haider S; Callen E; Hewitt G; Schimmel J; Prevo R; Alli C; Ferdinand A; Bell C; Blencowe P; Bot C; Calder M; Charles M; Curry J; Ekwuru T; Ewings K; Krajewski W; MacDonald E; McCarron H; Pang L; Pedder C; Rigoreau L; Swarbrick M; Wheatley E; Willis S; Wong AC; Nussenzweig A; Tijsterman M; Tutt A; Boulton SJ; Higgins GS; Pettitt SJ; Smith GCM; Lord CJ
Nat Commun; 2021 Jun; 12(1):3636. PubMed ID: 34140467
[TBL] [Abstract][Full Text] [Related]
4. Distinct roles of RAD52 and POLQ in chromosomal break repair and replication stress response.
Kelso AA; Lopezcolorado FW; Bhargava R; Stark JM
PLoS Genet; 2019 Aug; 15(8):e1008319. PubMed ID: 31381562
[TBL] [Abstract][Full Text] [Related]
5. DNA polymerase θ (POLQ), double-strand break repair, and cancer.
Wood RD; Doublié S
DNA Repair (Amst); 2016 Aug; 44():22-32. PubMed ID: 27264557
[TBL] [Abstract][Full Text] [Related]
6. Simultaneous Targeting of DNA Polymerase Theta and PARP1 or RAD52 Triggers Dual Synthetic Lethality in Homologous Recombination-Deficient Leukemia Cells.
Sullivan-Reed K; Toma MM; Drzewiecka M; Nieborowska-Skorska M; Nejati R; Karami A; Wasik MA; Sliwinski T; Skorski T
Mol Cancer Res; 2023 Oct; 21(10):1017-1022. PubMed ID: 37358557
[TBL] [Abstract][Full Text] [Related]
7. REV1-Polζ maintains the viability of homologous recombination-deficient cancer cells through mutagenic repair of PRIMPOL-dependent ssDNA gaps.
Taglialatela A; Leuzzi G; Sannino V; Cuella-Martin R; Huang JW; Wu-Baer F; Baer R; Costanzo V; Ciccia A
Mol Cell; 2021 Oct; 81(19):4008-4025.e7. PubMed ID: 34508659
[TBL] [Abstract][Full Text] [Related]
8. Co-inhibition of pol θ and HR genes efficiently synergize with cisplatin to suppress cisplatin-resistant lung cancer cells survival.
Dai CH; Chen P; Li J; Lan T; Chen YC; Qian H; Chen K; Li MY
Oncotarget; 2016 Oct; 7(40):65157-65170. PubMed ID: 27533083
[TBL] [Abstract][Full Text] [Related]
9. Polymerase θ inhibition steps on the cGAS pedal.
Smith CM; Gupta GP
J Clin Invest; 2023 Jun; 133(11):. PubMed ID: 37259920
[TBL] [Abstract][Full Text] [Related]
10. Homologous-recombination-deficient tumours are dependent on Polθ-mediated repair.
Ceccaldi R; Liu JC; Amunugama R; Hajdu I; Primack B; Petalcorin MI; O'Connor KW; Konstantinopoulos PA; Elledge SJ; Boulton SJ; Yusufzai T; D'Andrea AD
Nature; 2015 Feb; 518(7538):258-62. PubMed ID: 25642963
[TBL] [Abstract][Full Text] [Related]
11. DNA polymerase θ (POLQ) is important for repair of DNA double-strand breaks caused by fork collapse.
Wang Z; Song Y; Li S; Kurian S; Xiang R; Chiba T; Wu X
J Biol Chem; 2019 Mar; 294(11):3909-3919. PubMed ID: 30655289
[TBL] [Abstract][Full Text] [Related]
12. POLQ inhibition elicits an immune response in homologous recombination-deficient pancreatic adenocarcinoma via cGAS/STING signaling.
Oh G; Wang A; Wang L; Li J; Werba G; Weissinger D; Zhao E; Dhara S; Hernandez RE; Ackermann A; Porcella S; Kalfakakou D; Dolgalev I; Kawaler E; Golan T; Welling TH; Sfeir A; Simeone DM
J Clin Invest; 2023 Jun; 133(11):. PubMed ID: 36976649
[TBL] [Abstract][Full Text] [Related]
13. Synthetic Lethality Targeting Polθ.
Drzewiecka M; Barszczewska-Pietraszek G; Czarny P; Skorski T; Śliwiński T
Genes (Basel); 2022 Jun; 13(6):. PubMed ID: 35741863
[TBL] [Abstract][Full Text] [Related]
14. Crosstalk of DNA double-strand break repair pathways in poly(ADP-ribose) polymerase inhibitor treatment of breast cancer susceptibility gene 1/2-mutated cancer.
Sunada S; Nakanishi A; Miki Y
Cancer Sci; 2018 Apr; 109(4):893-899. PubMed ID: 29427345
[TBL] [Abstract][Full Text] [Related]
15. Tyrosine kinase inhibitor-induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitors.
Maifrede S; Nieborowska-Skorska M; Sullivan-Reed K; Dasgupta Y; Podszywalow-Bartnicka P; Le BV; Solecka M; Lian Z; Belyaeva EA; Nersesyan A; Machnicki MM; Toma M; Chatain N; Rydzanicz M; Zhao H; Jelinek J; Piwocka K; Sliwinski T; Stoklosa T; Ploski R; Fischer T; Sykes SM; Koschmieder S; Bullinger L; Valent P; Wasik MA; Huang J; Skorski T
Blood; 2018 Jul; 132(1):67-77. PubMed ID: 29784639
[TBL] [Abstract][Full Text] [Related]
16. Targeting Polymerase Theta (POLθ) for Cancer Therapy.
Patterson-Fortin J; D'Andrea AD
Cancer Treat Res; 2023; 186():285-298. PubMed ID: 37978141
[TBL] [Abstract][Full Text] [Related]
17. FEN1 endonuclease as a therapeutic target for human cancers with defects in homologous recombination.
Guo E; Ishii Y; Mueller J; Srivatsan A; Gahman T; Putnam CD; Wang JYJ; Kolodner RD
Proc Natl Acad Sci U S A; 2020 Aug; 117(32):19415-19424. PubMed ID: 32719125
[TBL] [Abstract][Full Text] [Related]
18. POLQ plays a key role in the repair of CRISPR/Cas9-induced double-stranded breaks in the moss Physcomitrella patens.
Mara K; Charlot F; Guyon-Debast A; Schaefer DG; Collonnier C; Grelon M; Nogué F
New Phytol; 2019 May; 222(3):1380-1391. PubMed ID: 30636294
[TBL] [Abstract][Full Text] [Related]
19. Breast Cancer Predisposition Genes and Synthetic Lethality.
Neiger HE; Siegler EL; Shi Y
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34070674
[No Abstract] [Full Text] [Related]
20. LMO2 Confers Synthetic Lethality to PARP Inhibition in DLBCL.
Parvin S; Ramirez-Labrada A; Aumann S; Lu X; Weich N; Santiago G; Cortizas EM; Sharabi E; Zhang Y; Sanchez-Garcia I; Gentles AJ; Roberts E; Bilbao-Cortes D; Vega F; Chapman JR; Verdun RE; Lossos IS
Cancer Cell; 2019 Sep; 36(3):237-249.e6. PubMed ID: 31447348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
